Showing results (531-540 of 552) with videos related to
Sort By:
Pageof 56
United European Gastroenterology Journal|October 19, 2020
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of careSimone Saibeni, Ludovica Scucchi, Gabriele Dragoni, et al.Advances in Therapy|June 30, 2026
Five-Year Real-World Hard Outcomes of Vedolizumab in Inflammatory Bowel Disease: The IG-IBD LONG-LIVE StudyGiuseppe Privitera, Flavia Palumbo, Fabio Salvatore Macaluso, et al.Expert Opinion on Pharmacotherapy|June 26, 2023
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world studyAntonio Tursi, Giammarco Mocci, Linda Cingolani, et al.American Journal of Hematology|July 19, 2026
Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE StudyAntonio M Risitano, Simona Iacobelli, Austin Kulasekararaj, et al.The British Journal of Surgery|July 21, 2023
IMMUNOREACT 6: weak immune surveillance characterizes early-onset rectal cancerGaya Spolverato, Matteo Fassan, Melania Scarpa, et al.Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 13, 2025
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning-the IG-IBD LIVE studyDaniela Pugliese, Giuseppe Privitera, Nicola Cersullo, et al.Expert Opinion on Biological Therapy|January 22, 2024
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life studyAntonio Tursi, Giammarco Mocci, Franco Scaldaferri, et al.Advances in Therapy|May 9, 2026
Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort StudyAntonio Tursi, Andrea Pasta, Walter Elisei, et al.Journal of Clinical Medicine|November 13, 2025
Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World StudyGiammarco Mocci, Antonio Tursi, Franco Scaldaferri, et al.Oncology and Therapy|January 10, 2024
Non-Small Cell Lung Cancer Testing on Reference Specimens: An Italian Multicenter ExperienceFrancesco Pepe, Gianluca Russo, Alessandro Venuta, et al.Pageof 56